Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Moderna Inc. MRNA stock is trading lower after it rallied around 170% on Wednesday on upbeat data from individualized cancer ...

“It’s very exciting,” a melanoma expert said of the experimental cancer vaccine announced by pharmaceutical companies Moderna ...

Merck MRK is increasingly relying on the growing portfolio of newer products, recent acquisitions and pipeline candidates to ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Adults at high risk of melanoma recurrence and spread were able to stay cancer-free with personalized vaccines made with mRNA ...

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term ...